The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $31.42, up 3.02% from its previous closing price of $30.50. In other words, the price has increased by $3.02 from its previous closing price. On the day, 1.04 million shares were traded. RNA stock price reached its highest trading level at $32.5 during the session, while it also had its lowest trading level at $30.12.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, initiated with a Buy rating and assigned the stock a target price of $72.
On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.Goldman initiated its Buy rating on September 24, 2024, with a $59 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 18 ’24 when Flanagan W. Michael sold 12,742 shares for $32.66 per share. The transaction valued at 416,154 led to the insider holds 72,647 shares of the business.
MacLean Michael F sold 11,151 shares of RNA for $364,192 on Dec 18 ’24. The Chief Financial Officer now owns 82,942 shares after completing the transaction at $32.66 per share. On Dec 18 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 31,855 shares for $32.66 each. As a result, the insider received 1,040,384 and left with 265,308 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3748688896 and an Enterprise Value of 2167706624. For the stock, the TTM Price-to-Sale (P/S) ratio is 362.35 while its Price-to-Book (P/B) ratio in mrq is 2.48. Its current Enterprise Value per Revenue stands at 214.264 whereas that against EBITDA is -6.731.
Stock Price History:
The Beta on a monthly basis for RNA is 0.99, which has changed by 1.6614311 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $8.95. The 50-Day Moving Average of the stock is -20.26%, while the 200-Day Moving Average is calculated to be -16.19%.
Shares Statistics:
It appears that RNA traded 1.10M shares on average per day over the past three months and 1310230 shares per day over the past ten days. A total of 118.90M shares are outstanding, with a floating share count of 108.55M. Insiders hold about 9.02% of the company’s shares, while institutions hold 101.12% stake in the company. Shares short for RNA as of 1734048000 were 15476155 with a Short Ratio of 14.07, compared to 1731628800 on 14516927. Therefore, it implies a Short% of Shares Outstanding of 15476155 and a Short% of Float of 16.0.
